Gentris Corporation, a startup clinical pharmacogenomics testing and diagnostic products company, and Promega Corporation, a Madison WI-based supplier of biological reagents and reagent systems, have entered an agreement to jointly pursue development of clinical pharmacogenomic products.

The purpose of the agreement, the companies say, is to combine their “leading edge technologies” into a “robotic liquid handling platform” to produce clinical pharmacogenomic products. Tests of this type will enable physicians to make decisions regarding appropriate prescription drugs and dosing for their patients, they say.

“Promega’s READIT Technology, and MagneSil Systems combined with Gentris technologies will bring a turnkey solution that clinical diagnostic labs need for implementing pharmacogenomic testing,” Michael P. Murphy, president and chief executive officer of Gentris, said in a statement.

Gentris says it develops products to predict drug efficacy and to decrease adverse drug reactions and provides pharmaceutical research organizations with pharmacogenomic solutions to improve the efficiency and predictability of drug development. The ultimate benefit to these organizations is to shorten drug development cycles, improve new drug approval rates and allow drugs that might have otherwise been abandoned advance towards final approval and be prescribed to a targeted subset of the population.

Promega provides solutions for the life sciences industry. The company says its 1,200 products enable scientists worldwide to advance knowledge in genomics, proteomics, cellular analysis, molecular diagnostics, drug discovery and human identification. Founded in 1978, Promega has eight branch offices and over 50 distributors throughout the world. Annual sales exceed $125 million.